Seeking Alpha


Send Message
View as an RSS Feed
View eyalillouz's Comments BY TICKER:
Latest  |  Highest rated
  • Rexahn: A Turn Around Story For 2014 [View article]
    RNN has real compounds which should (hopefully) limit the downside risks. However, what strikes as 'odd', is for TEVA to stop its licensing agreement with RNN, and especially with the promise of the large oncology market, in addition to its expiring blockbuster drug (copaxone). For TEVA's deep pockets, forward-thinking vision, one would assume RNN's product pipeline is one risk TEVA would be willing to assume - at all cost.
    Dec 22 02:12 PM | Likes Like |Link to Comment
  • Teva Pharmaceuticals: Beaten, Bludgeoned And Brutalized - It's A Buy [View article]
    Good article -

    A correction should take place in the foreseeable future, of which the fundamentals you elaborated on support this, and with expansions in new markets, namely South East Asia. Geopolitical risks are however not negligible -

    In addition, market sentiment has been biased against Teva, with a higher put/call ratio, and with a preference, it seems, to a company like Mylan...
    Feb 4 08:11 PM | Likes Like |Link to Comment